CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,700 enrolled
Drug / intervention
Treatment for Fibromyalgiadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00725101
NCT00725101N/ACompleted
CompareCT.gov

Real World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments (The REFLECTIONS Study)

Eli Lilly and Company·observational·Posted Jul 30, 2008·Updated Nov 30, 2012

In Brief

An observational study evaluating Treatment for Fibromyalgia for Fibromyalgia. Completed, enrolled 1,700 participants across 58 sites in 2 countries.

Detailed Summary

The Real World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments (REFLECTIONS) Study is a 12-month, prospective observational study that will be utilized in approximately 58 care settings in the United States (US) and Puerto Rico. It is designed to examine treatment patterns and health outcomes of adult participants diagnosed by their physician with fibromyalgia (FM) and who are starting any "new pharmacologic agent" for FM. The primary benefit of this study is enhanced understanding of the disease state of FM and the role that pharmacologic treatment plays, which may help to optimize management of FM. This study will address current gaps in a rapidly growing body of literature on FM.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesPuerto Rico, United States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartJun 1, 2008
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.9 years ago

Interventions

Treatment for Fibromyalgiadrug

FM participants starting any new pharmacologic FM agent.